Journal Article
. 2012 May;30(18).
doi: 10.1200/JCO.2011.40.1273.

Decline in the use of anthracyclines for breast cancer

Sharon H Giordano 1 Yu-Li Lin  Yong Fang Kuo  Gabriel N Hortobagyi  James S Goodwin  
Affiliations
  • PMID: 22614988
  •     18 References
  •     61 citations

Abstract

Purpose: To determine the patterns of use of anthracycline- and taxane-based chemotherapy for breast cancer treatment.

Methods: Claims from a 5% national Medicare sample and from a nationally representative claims database (Marketscan) from 1998 to 2009 were used. Patients with International Classification of Diseases (ICD), ninth revision, codes indicating breast cancer, ICD and Common Procedural Terminology codes indicating breast surgery, and claims for chemotherapy between 3 months before and 12 months after surgery comprised the study cohort. Chemotherapy was classified as anthracycline-based or taxane-based, and the percentages of use were calculated. Piecewise regression models were used to identify the inflection points in the rates of chemotherapy use. The effect of patient characteristics on receiving different types of chemotherapy was estimated by multivariable logistic regression models.

Results: A total of 4,458 patients were included in the Medicare cohort and 30,422 in the private insurance cohort. After 2005, a sharp increase in the use of taxane-based chemotherapy and a decline in anthracycline-based chemotherapy was seen. By 2008 in the Medicare cohort, 51% of patients received taxane-based and 32% received anthracycline-based chemotherapy. By the end of 2008, the majority of patients younger than 65 years were also receiving taxane-based chemotherapy. Patients younger than 35 years were less likely to be treated with a taxane-based regimen, whereas patients who underwent 21-gene recurrence score testing and those treated with trastuzumab were more likely to receive taxane-based chemotherapy.

Conclusion: The use of anthracycline-based chemotherapy has declined, and the majority of patients with breast cancer are instead receiving taxane-based chemotherapy. The potential impact on patient outcomes is unknown.

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
Stephen E Jones, Michael A Savin, +17 authors, Lina Asmar.
J Clin Oncol, 2006 Dec 01; 24(34). PMID: 17135639
Highly Cited.
Impact of a scientific presentation on community treatment patterns for primary breast cancer.
Sharon H Giordano, Zhigang Duan, +3 authors, James S Goodwin.
J Natl Cancer Inst, 2006 Mar 16; 98(6). PMID: 16537830    Free PMC article.
Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.
Mary C Pinder, Zhigang Duan, +2 authors, Sharon H Giordano.
J Clin Oncol, 2007 Aug 01; 25(25). PMID: 17664460
Highly Cited.
Evaluation of three algorithms to identify incident breast cancer in Medicare claims data.
Heather T Gold, Huong T Do.
Health Serv Res, 2007 Sep 14; 42(5). PMID: 17850533    Free PMC article.
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.
Martine J Piccart-Gebhart, Tomasz Burzykowski, +13 authors, Patrick Therasse.
J Clin Oncol, 2008 Apr 19; 26(12). PMID: 18421049
Weekly paclitaxel in the adjuvant treatment of breast cancer.
Joseph A Sparano, Molin Wang, +7 authors, Nancy E Davidson.
N Engl J Med, 2008 Apr 19; 358(16). PMID: 18420499    Free PMC article.
Highly Cited.
Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer.
Margot Burnell, Mark N Levine, +11 authors, Lois E Shepherd.
J Clin Oncol, 2009 Nov 11; 28(1). PMID: 19901117    Free PMC article.
Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.
Rebecca Siegel, Elizabeth Ward, Otis Brawley, Ahmedin Jemal.
CA Cancer J Clin, 2011 Jun 21; 61(4). PMID: 21685461
Highly Cited.
Adjuvant trastuzumab in HER2-positive breast cancer.
Dennis Slamon, Wolfgang Eiermann, +21 authors, Breast Cancer International Research Group.
N Engl J Med, 2011 Oct 14; 365(14). PMID: 21991949    Free PMC article.
Highly Cited.
An approach to identifying incident breast cancer cases using Medicare claims data.
J L Freeman, D Zhang, D H Freeman, J S Goodwin.
J Clin Epidemiol, 2000 Jul 06; 53(6). PMID: 10880779
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
I Craig Henderson, Donald A Berry, +16 authors, Larry Norton.
J Clin Oncol, 2003 Mar 15; 21(6). PMID: 12637460
Highly Cited.
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Marc L Citron, Donald A Berry, +18 authors, Larry Norton.
J Clin Oncol, 2003 Apr 02; 21(8). PMID: 12668651
Highly Cited.
An algorithm for the use of Medicare claims data to identify women with incident breast cancer.
Ann B Nattinger, Purushottam W Laud, +2 authors, Jean L Freeman.
Health Serv Res, 2004 Nov 10; 39(6 Pt 1). PMID: 15533184    Free PMC article.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.
Eleftherios P Mamounas, John Bryant, +7 authors, Norman Wolmark.
J Clin Oncol, 2005 May 18; 23(16). PMID: 15897552
Highly Cited.
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
Edward H Romond, Edith A Perez, +22 authors, Norman Wolmark.
N Engl J Med, 2005 Oct 21; 353(16). PMID: 16236738
Highly Cited.
Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000.
Linda C Harlan, Limin X Clegg, +2 authors, Rachel Ballard-Barbash.
J Clin Oncol, 2006 Feb 18; 24(6). PMID: 16484696
Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988-2003 SEER data.
Jennifer Gnerlich, Donna B Jeffe, +3 authors, Julie A Margenthaler.
Ann Surg Oncol, 2007 May 25; 14(8). PMID: 17522944
Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007.
Allison W Kurian, Daphne Y Lichtensztajn, +8 authors, Scarlett L Gomez.
Breast Cancer Res Treat, 2012 Nov 10; 137(1). PMID: 23139057    Free PMC article.
Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists.
Rena M Conti, Arielle C Bernstein, +3 authors, Peter B Bach.
J Clin Oncol, 2013 Feb 21; 31(9). PMID: 23423747    Free PMC article.
The impact of emerging safety and effectiveness evidence on the use of physician-administered drugs: the case of bevacizumab for breast cancer.
Rena M Conti, Stacie B Dusetzina, +3 authors, Nancy L Keating.
Med Care, 2013 Apr 23; 51(7). PMID: 23604014    Free PMC article.
Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer.
Jennifer B Dennison, Jennifer R Molina, +9 authors, Gordon B Mills.
Clin Cancer Res, 2013 May 24; 19(13). PMID: 23697991    Free PMC article.
A new mathematical pharmacodynamic model of clonogenic cancer cell death by doxorubicin.
Jan Lankelma, Rafael Fernández Luque, +2 authors, Bob Kooi.
J Pharmacokinet Pharmacodyn, 2013 Jul 19; 40(4). PMID: 23864485
LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer.
Francesca Lovat, Hideshi Ishii, +7 authors, Andrea Vecchione.
Oncotarget, 2014 Jan 23; 5(4). PMID: 24448468    Free PMC article.
Problems with public reporting of cancer quality outcomes data.
Paul Goldberg, Rena M Conti.
J Oncol Pract, 2014 May 20; 10(3). PMID: 24839285    Free PMC article.
Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer.
Carlos H Barcenas, Jiangong Niu, +6 authors, Sharon H Giordano.
J Clin Oncol, 2014 May 29; 32(19). PMID: 24868022    Free PMC article.
Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines.
Jennifer A Crozier, Abhisek Swaika, Alvaro Moreno-Aspitia.
World J Clin Oncol, 2014 Aug 13; 5(3). PMID: 25114866    Free PMC article.
Review.
Chemotherapy in early breast cancer: when, how and which one?
Marcus Schmidt.
Breast Care (Basel), 2014 Sep 02; 9(3). PMID: 25177256    Free PMC article.
Review.
The diffusion of docetaxel in patients with metastatic prostate cancer.
Joseph M Unger, Dawn L Hershman, +4 authors, Scott R Ramsey.
J Natl Cancer Inst, 2014 Dec 30; 107(2). PMID: 25540245    Free PMC article.
A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer.
Changhoon Yoo, Sung-Bae Kim, +9 authors, Woo Kun Kim.
Cancer Res Treat, 2015 Feb 05; 47(3). PMID: 25648092    Free PMC article.
Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition.
Aaron Goldman, Biswanath Majumder, +5 authors, Shiladitya Sengupta.
Nat Commun, 2015 Feb 12; 6. PMID: 25669750    Free PMC article.
Highly Cited.
Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study.
Ines Vaz-Luis, Melissa E Hughes, +7 authors, Nancy U Lin.
Cancer, 2015 Mar 12; 121(12). PMID: 25757412    Free PMC article.
Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort.
Meyha N Swaroop, Chantal M Ferguson, +8 authors, Alphonse G Taghian.
Breast Cancer Res Treat, 2015 May 06; 151(2). PMID: 25940996    Free PMC article.
Cardiotoxicity of anticancer treatments.
Michael S Ewer, Steven M Ewer.
Nat Rev Cardiol, 2015 May 13; 12(9). PMID: 25962976
Highly Cited. Review.
How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab.
Stacie B Dusetzina, Shellie Ellis, +6 authors, Nancy L Keating.
J Oncol Pract, 2015 Jun 11; 11(4). PMID: 26060224    Free PMC article.
Rates of BRCA1/2 mutation testing among young survivors of breast cancer.
Kenneth L Kehl, Chan Shen, +2 authors, Sharon H Giordano.
Breast Cancer Res Treat, 2015 Dec 27; 155(1). PMID: 26706041    Free PMC article.
Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines.
Daniel L Hertz, Megan V Caram, +10 authors, James M Rae.
Pharmacogenomics, 2016 Jan 23; 17(3). PMID: 26799497    Free PMC article.
Tumor characteristics and therapy of elderly patients with breast cancer.
A-M Grumpelt, A Ignatov, +3 authors, H Eggemann.
J Cancer Res Clin Oncol, 2016 Jan 27; 142(5). PMID: 26809246
An Application of the Multivariate Linear Mixed Model to the Analysis of Shoulder Complexity in Breast Cancer Patients.
Gholamreza Oskrochi, Emmanuel Lesaffre, Youssof Oskrochi, Delva Shamley.
Int J Environ Res Public Health, 2016 Mar 08; 13(3). PMID: 26950134    Free PMC article.
Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity.
Paul W Burridge, Yong Fuga Li, +14 authors, Joseph C Wu.
Nat Med, 2016 Apr 19; 22(5). PMID: 27089514    Free PMC article.
Highly Cited.
Safety, Effectiveness, and Costs of Bevacizumab-Based Therapy in Southern Spain: A Real World Experience.
Juan F Marín-Pozo, Juan M Duarte-Pérez, Pedro Sánchez-Rovira.
Medicine (Baltimore), 2016 May 14; 95(19). PMID: 27175672    Free PMC article.
Stem cells: The cancer's gone, but did chemotherapy damage your heart?
Milena Bellin, Christine L Mummery.
Nat Rev Cardiol, 2016 May 27; 13(7). PMID: 27226155
HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
Kathy Miller, Javier Cortes, +8 authors, Denise A Yardley.
BMC Cancer, 2016 Jun 05; 16. PMID: 27259714    Free PMC article.
Receipt of Cancer Screening Is a Predictor of Life Expectancy.
James S Goodwin, Kristin Sheffield, Shuang Li, Alai Tan.
J Gen Intern Med, 2016 Oct 21; 31(11). PMID: 27364834    Free PMC article.
A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer.
Xi Jin, Yi-Zhou Jiang, +5 authors, Gen-Hong Di.
BMC Cancer, 2016 Aug 09; 16. PMID: 27495967    Free PMC article.
Second Opinions From Medical Oncologists for Early-Stage Breast Cancer: Prevalence, Correlates, and Consequences.
Allison W Kurian, Christopher R Friese, +5 authors, Steven J Katz.
JAMA Oncol, 2016 Dec 30; 3(3). PMID: 28033448    Free PMC article.
Anthracycline Chemotherapy and Cardiotoxicity.
John V McGowan, Robin Chung, +3 authors, Derek M Yellon.
Cardiovasc Drugs Ther, 2017 Feb 12; 31(1). PMID: 28185035    Free PMC article.
Highly Cited. Review.
Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer.
Hope S Rugo, Paula Klein, +10 authors, Tessa Cigler.
JAMA, 2017 Feb 15; 317(6). PMID: 28196257    Free PMC article.
Survival benefit needed to undergo chemotherapy: Patient and physician preferences.
Ines Vaz-Luis, Anne O'Neill, +8 authors, Ann H Partridge.
Cancer, 2017 Mar 23; 123(15). PMID: 28323331    Free PMC article.
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
Joanne L Blum, Patrick J Flynn, +19 authors, Norman Wolmark.
J Clin Oncol, 2017 Apr 12; 35(23). PMID: 28398846    Free PMC article.
Highly Cited.
Weight change during chemotherapy in breast cancer patients: a meta-analysis.
M M G A van den Berg, R M Winkels, +5 authors, E Kampman.
BMC Cancer, 2017 Apr 14; 17(1). PMID: 28403873    Free PMC article.
Phase II study of adjuvant docetaxel and carboplatin with/without doxorubicin and cyclophosphamide in triple negative breast cancer: a randomised controlled clinical trial.
Safa Najafi, Mehrdad Payandeh, +3 authors, Fereshte Abbasvandi.
Contemp Oncol (Pozn), 2017 Apr 25; 21(1). PMID: 28435404    Free PMC article.
APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial.
Ian D Schnadig, Richy Agajanian, +9 authors, Nicholas Vogelzang.
Cancer Manag Res, 2017 Jun 06; 9. PMID: 28579832    Free PMC article.
Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
Anthony F Yu, Roy B Mukku, +5 authors, Chau T Dang.
Breast Cancer Res Treat, 2017 Jul 16; 166(1). PMID: 28710537    Free PMC article.
Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies.
Roberta Florido, Karen L Smith, Kimberly K Cuomo, Stuart D Russell.
J Am Heart Assoc, 2017 Sep 25; 6(9). PMID: 28939718    Free PMC article.
Review.
Incidence, Diagnosis, and Treatment of Cardiac Toxicity from Trastuzumab in Patients with Breast Cancer.
Somaira Nowsheen, Paul V Viscuse, +7 authors, Kathryn J Ruddy.
Curr Breast Cancer Rep, 2017 Dec 12; 9(3). PMID: 29225726    Free PMC article.
Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients.
Aron S Rosenstock, Jiangong Niu, +3 authors, Mariana Chavez-MacGregor.
Cancer, 2017 Dec 14; 124(5). PMID: 29236294    Free PMC article.
Native myocardial T1 time can predict development of subsequent anthracycline-induced cardiomyopathy.
Fabian Muehlberg, Stephanie Funk, +7 authors, Jeanette Schulz-Menger.
ESC Heart Fail, 2018 Apr 20; 5(4). PMID: 29673122    Free PMC article.
Conditional relative survival among long-term survivors of adolescent and young adult cancers.
Chelsea Anderson, Andrew B Smitherman, Hazel B Nichols.
Cancer, 2018 May 10; 124(14). PMID: 29742278    Free PMC article.
A SIRT1-centered circuitry regulates breast cancer stemness and metastasis.
Lei Shi, Xiaolong Tang, +8 authors, Baohua Liu.
Oncogene, 2018 Jul 25; 37(49). PMID: 30038266    Free PMC article.
Treatment patterns for adjuvant docetaxel-based chemotherapy in early-stage breast cancer in China: A pooled retrospective analysis of four observational studies.
Binghe Xu, Zhimin Shao, +7 authors, Shu Wang.
Chin J Cancer Res, 2018 Jul 27; 30(3). PMID: 30046227    Free PMC article.
The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers.
Safa Najafi, Masoud Sadeghi, +2 authors, Kamran Mohebi.
Contemp Oncol (Pozn), 2018 Aug 29; 22(2). PMID: 30150888    Free PMC article.
Impact of 21-Gene Recurrence Score on Chemotherapy Decision in Invasive Ductal Carcinoma of Breast with Nodal Micrometastases.
Wei-Rong Chen, Jia-Peng Deng, +3 authors, San-Gang Wu.
Cancer Res Treat, 2019 Mar 28; 51(4). PMID: 30913871    Free PMC article.
Heart Failure in Relation to Anthracyclines and Other Chemotherapies.
Tolulope A Agunbiade, Raja Y Zaghlol, Ana Barac.
Methodist Debakey Cardiovasc J, 2020 Jan 29; 15(4). PMID: 31988684    Free PMC article.
Review.
Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study.
Pamela Munster, Ian E Krop, +12 authors, Kathy D Miller.
Br J Cancer, 2018 Oct 27; 119(9). PMID: 30361524    Free PMC article.
Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy?
Abiola F Ibraheem, David J Press, Olufunmilayo I Olopade, Dezheng Huo.
Cancer, 2018 Nov 06; 125(2). PMID: 30387876    Free PMC article.
The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity.
Kerstin N Timm, Damian J Tyler.
Cardiovasc Drugs Ther, 2020 Feb 09; 34(2). PMID: 32034646    Free PMC article.
Review.
Doxorubicin-induced cardiotoxicity is maturation dependent due to the shift from topoisomerase IIα to IIβ in human stem cell derived cardiomyocytes.
Ning Cui, Fujian Wu, +6 authors, Ming Cui.
J Cell Mol Med, 2019 May 21; 23(7). PMID: 31106979    Free PMC article.
Trends in the use of primary prophylactic colony-stimulating factors and neutropenia-related hospitalization in elderly cancer patients receiving myelosuppressive chemotherapy in the USA: 1995-2015.
Shuling Li, Jiannong Liu, +4 authors, David Chandler.
Support Care Cancer, 2019 Oct 19; 28(6). PMID: 31624920
Real-world impact of postmastectomy radiotherapy in T1-2 breast cancer with one to three positive lymph nodes.
Feng-Yan Li, Chen-Lu Lian, +4 authors, San-Gang Wu.
Ann Transl Med, 2020 May 13; 8(7). PMID: 32395533    Free PMC article.
Simulation of Chemotherapy Effects in Older Breast Cancer Patients With High Recurrence Scores.
Young Chandler, Jinani C Jayasekera, +3 authors, Jeanne S Mandelblatt.
J Natl Cancer Inst, 2019 Oct 16; 112(6). PMID: 31612208    Free PMC article.
Remote Ischemic Pre-Conditioning Attenuates Adverse Cardiac Remodeling and Mortality Following Doxorubicin Administration in Mice.
Zachary M Gertz, Chad Cain, +9 authors, Fadi N Salloum.
JACC CardioOncol, 2020 Jul 24; 1(2). PMID: 32699841    Free PMC article.
Albumin-Albumin/Lactosylated Core-Shell Nanoparticles: Therapy to Treat Hepatocellular Carcinoma for Controlled Delivery of Doxorubicin.
Nayelli Guadalupe Teran-Saavedra, Jose Andrei Sarabia-Sainz, +3 authors, Luz Vazquez-Moreno.
Molecules, 2020 Nov 26; 25(22). PMID: 33233564    Free PMC article.
Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients.
Rurina Watanuki, Tetsu Hayashida, +7 authors, Yuko Kitagawa.
Int J Clin Oncol, 2019 Feb 28; 24(7). PMID: 30810890
Topoisomerases inhibition and DNA binding mode of daunomycin-oligoarginine conjugate.
Valeria Visone, Ildikó Szabó, +3 authors, Anna Valenti.
J Enzyme Inhib Med Chem, 2020 Jun 20; 35(1). PMID: 32552137    Free PMC article.
Clinical utilization of long-acting granulocyte colony-stimulating factor (pegfilgrastim) prophylaxis in breast cancer patients with adjuvant docetaxel-cyclophosphamide chemotherapy.
Ye Won Jeon, Seung Taek Lim, +4 authors, Young Jin Suh.
Ann Surg Treat Res, 2021 Feb 16; 100(2). PMID: 33585350    Free PMC article.
Risk of contralateral breast cancer according to first breast cancer characteristics among women in the USA, 1992-2016.
Cody Ramin, Diana R Withrow, +2 authors, Amy Berrington de González.
Breast Cancer Res, 2021 Feb 19; 23(1). PMID: 33596988    Free PMC article.
Drug Combination in Cancer Treatment-From Cocktails to Conjugated Combinations.
Yosi Gilad, Gary Gellerman, David M Lonard, Bert W O'Malley.
Cancers (Basel), 2021 Feb 11; 13(4). PMID: 33562300    Free PMC article.
Review.
Structural and Electrophysiological Changes in a Model of Cardiotoxicity Induced by Anthracycline Combined With Trastuzumab.
Claudia Altomare, Alessandra Maria Lodrini, +10 authors, Giuseppe Vassalli.
Front Physiol, 2021 Apr 27; 12. PMID: 33897465    Free PMC article.